Cancer Research AACR Membership  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 68, 1462, March 1, 2008. doi: 10.1158/0008-5472.CAN-07-3094
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neil, J. R.
Right arrow Articles by Schiemann, W. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neil, J. R.
Right arrow Articles by Schiemann, W. P.

Cell, Tumor, and Stem Cell Biology

Altered TAB1:I{kappa}B Kinase Interaction Promotes Transforming Growth Factor β–Mediated Nuclear Factor-{kappa}B Activation during Breast Cancer Progression

Jason R. Neil and William P. Schiemann

Department of Pharmacology, University of Colorado Health Sciences Center, Aurora, Colorado

Requests for reprints: William P. Schiemann, Department of Pharmacology, University of Colorado Health Sciences Center, RC1 South Tower, Room L18-6110, 12801 East 17th Avenue, P.O. Box 6511, Aurora, CO 80045. Phone: 303-724-1541; Fax: 303-724-3663; E-mail: Bill.Schiemann{at}uchsc.edu.

Key Words: Breast Cancer • NF-{kappa}B • TAB1 • TAK1 • TGF-β

The conversion of transforming growth factor β (TGF-β) from a tumor suppressor to a tumor promoter occurs frequently during mammary tumorigenesis, yet the molecular mechanisms underlying this phenomenon remain undefined. We show herein that TGF-β repressed nuclear factor-{kappa}B (NF-{kappa}B) activity in normal NMuMG cells, but activated this transcription factor in their malignant counterparts, 4T1 cells, by inducing assembly of TGF-β–activated kinase 1 (TAK1)–binding protein 1 (TAB1):I{kappa}B kinase β (IKKβ) complexes, which led to the stimulation of a TAK1:IKKβ:p65 pathway. TAB1:IKKβ complexes could only be detected in NMuMG cells following their induction of epithelial-mesenchymal transition (EMT), which, on TGF-β treatment, activated NF-{kappa}B. Expression of a truncated TAB1 mutant [i.e., TAB1(411)] reduced basal and TGF-β–mediated NF-{kappa}B activation in NMuMG cells driven to undergo EMT by TGF-β and in 4T1 cells stimulated by TGF-β. TAB1(411) expression also inhibited TGF-β–stimulated tumor necrosis factor-{alpha} and cyclooxygenase-2 expression in 4T1 cells. Additionally, the ability of human MCF10A-CA1a breast cancer cells to undergo invasion in response to TGF-β absolutely required the activities of TAK1 and NF-{kappa}B. Moreover, small interfering RNA–mediated TAK1 deficiency restored the cytostatic activity of TGF-β in MCF10A-CA1a cells. Finally, expression of truncated TAB1(411) dramatically reduced the growth of 4T1 breast cancers in syngeneic BALB/c, as well as in nude mice, suggesting a potentially important role of NF-{kappa}B in regulating innate immunity by TGF-β. Collectively, our findings have defined a novel TAB1:TAK1:IKKβ:NF-{kappa}B signaling axis that forms aberrantly in breast cancer cells and, consequently, enables oncogenic signaling by TGF-β. [Cancer Res 2008;68(5):1462–70]




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
J. R. Neil, M. Tian, and W. P. Schiemann
X-linked Inhibitor of Apoptosis Protein and Its E3 Ligase Activity Promote Transforming Growth Factor-{beta}-mediated Nuclear Factor-{kappa}B Activation during Breast Cancer Progression
J. Biol. Chem., August 7, 2009; 284(32): 21209 - 21217.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
H. J. You, T. How, and G. C. Blobe
The type III transforming growth factor-{beta} receptor negatively regulates nuclear factor kappa B signaling through its interaction with {beta}-arrestin2
Carcinogenesis, August 1, 2009; 30(8): 1281 - 1287.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
P. Bendinelli, E. Matteucci, P. Maroni, and M. A. Desiderio
NF-{kappa}B Activation, Dependent on Acetylation/Deacetylation, Contributes to HIF-1 Activity and Migration of Bone Metastatic Breast Carcinoma Cells
Mol. Cancer Res., August 1, 2009; 7(8): 1328 - 1341.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
J. R. Neil, K. M. Johnson, R. A. Nemenoff, and W. P. Schiemann
Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-{beta} through a PGE2-dependent mechanisms
Carcinogenesis, November 1, 2008; 29(11): 2227 - 2235.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.